Skip to content

Diagnose underlying aetiology with Intravascular Assessment versus Cardiac Magnetic Resonance Imaging in patients with Myocardial Infarction with Non-Obstructive Coronary Arteries (DETECT-MINOCA)

Diagnose underlying aetiology with Intravascular Assessment versus Cardiac Magnetic Resonance Imaging in patients with Myocardial Infarction with Non-Obstructive Coronary Arteries (DETECT-MINOCA)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12625000540415
Acronym
DETECT-MINOCA
Enrollment
1
Registered
2025-05-28
Start date
2025-07-15
Completion date
2027-07-01
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Current international guideline suggest that physicians should consider cath-lab based (eg. Intravascular imaging and vasoreactivity testing) and non-invasive investigations (eg. Echocardiography and cardiac MRI) for patients with myocardial infarction with non-obstructive arteries. However, there is no consensus as to which investigations should be performed and in what order. The aim of this study is to determine if using additional intravascular imaging in up to all 3 major coronary arteries would improve the diagnostic yield and reduce length of hospital stay in patients compared to inpatient cardiac MRI

Interventions

DETECT-MINOCA Algorithmic Pathway (Intervention Arm) - Participants randomised to the DETECT-MINOCA algorithm undergo further investigation stratified by their Left Ventricular Ejection Fraction (LVEF) and regional wall motion patterns: A) Patients with preserved LVEF or regional wall motion abnormalities: - Optical Coherence Tomography (OCT): Performed immediately following coronary angiography in the catheterisation lab. OCT uses a near-infrared light source delivered via an intracoronary ca

DETECT-MINOCA Algorithmic Pathway (Intervention Arm) - Participants randomised to the DETECT-MINOCA algorithm undergo further investigation stratified by their Left Ventricular Ejection Fraction (LVEF) and regional wall motion patterns: A) Patients with preserved LVEF or regional wall motion abnormalities: - Optical Coherence Tomography (OCT): Performed immediately following coronary angiography in the catheterisation lab. OCT uses a near-infrared light source delivered via an intracoronary catheter to image vessel morphology with high resolution. A small amount of contrast (~15mL) is used during image acquisition per vessel. The procedure takes approximately 10–15 minutes.for one vessel and 15-20 minutes for all 3 epicardial vessels. - Acetylcholine (ACh) Provocation Testing (optional): If OCT does not yield a definitive diagnosis, intracoronary ACh is administered to test for vasospasm. A 20–100 µg dose is injected directly into the coronary artery, with angiographic monitoring for vasoconstriction and symptoms. This adds approximately 5 minutes to the procedure. In some cases (e.g., RCA testing), a temporary pacing wire may be inserted as a safety precaution. - Cardiac Magnetic Resonance Imaging (CMR): If both OCT and ACh-provocation yields no diagnosis, CMR is performed as an inpatient prior to discharge. It involves a 30–40 minute scanning session with cine imaging, late gadolinium enhancement (LGE), and T1/T2 mapping. Gadolinium contrast (0.2 mmol/kg) is administered intravenously. CMR identifies both ischaemic and non-ischaemic myocardial injury. B) Patients with reduced LVEF and regional wall motion abnormality: These patients also proceed with OCT ± ACh testing, prioritising the vessel corresponding to the affected myocardial territory. If no pathology is found in the suspected culprit artery, OCT ± ACh may be extended to the remaining vessels. CMR is conducted if invasive testing yields no diagnosis. C) Patients with globally or severely reduced LVEF: These patients bypass invasive assessment and proceed directly to CMR. Timing: All invasive assessments (OCT ± ACh) are conducted within the index coronary angiogram procedure (i.e., immediately after angiographic diagnosis of MINOCA). CMR, if indicated, is performed within the index hospital admission, typically within 2–3 days of admission.

Sponsors

Sydney Local Health District
Lead SponsorGovernment body

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Diagnosis
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

- Adult men and women aged over 18 - Acute coronary syndrome with a raised high-sensitivity troponin. - No other obvious competing causes of demand ischaemia eg. arrhythmia, PE, sepsis. - Clinically referred for invasive coronary angiography - Coronary angiography diagnosis of non-obstructive coronary arteries (0.8) - Able to personally read and understand the Participant Information and Consent Form and provide written, signed and data informed consent to participate in study (health care interpreters will be engaged for people with cultural and linguistically diverse backgrounds).

Exclusion criteria

- Cardiogenic shock - Coronary angiography revealing obstructive coronary arteries (above or equal to 50% stenosis) - Acute myocardial infarction with fibrinolytic therapy - Stage IV/V Kidney disease ie. estimated glomerular filtration rate < 30 ml/m2 - Active internal bleeding - Previous coronary artery bypass surgery - Pregnancy or lactation. Women of childbearing potential must have a negative pregnancy test done prior to enrolment - Inability to provide informed consent (compromised mental status e.g., dementia, too ill) for clinically indicated coronary angiography - Currently a prisoner (has been admitted to hospital via a correctional facility) - Contraindications to contrast - Heavily calcified or tortuous vessels leading inability to advance OCT - Contraindications to cardiac magnetic resonance imaging (CMR) eg. metal implants, incompatible pacemaker/defibrillator, metal rods, screws, plates

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026